[1]Ktistakis NT, Tooze SA. Digesting the expanding mechanisms of autophagy\[J\]. Trends Cell Biol, 2016, 26(8): 624-635.
[2]Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms\[J\]. Autophagy, 2018, 14(2): 207-215.
[3]Cuervo AM, Wong E. Chaperonemediated autophagy: roles in disease and aging\[J\]. Cell Res, 2014, 24(1): 92-104.
[4]Condello M, Pellegrini E, Caraglia M, et al. Targeting autophagy to overcome human diseases\[J\]. Int J Mol Sci, 2019, 20(3): 725.
[5]Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact\[J\]. Mol Cell, 2012, 48(4): 491-507.
[6]Shin HJ, Kim H, Oh S, et al. AMPKSKP2CARM1 signalling cascade in transcriptional regulation of autophagy\[J\]. Nature, 2016, 534(7608): 553-557.
[7]Wei FZ, Cao Z, Wang X, et al. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an mTORdependent pathway\[J\]. Autophagy, 2015, 11(12): 2309-2322.
[8]ArtalMartinez de Narvajas A, Gomez TS, Zhang JS, et al. Epigenetic regulation of autophagy by the methyltransferase G9a\[J\]. Mol Cell Biol, 2013, 33(20): 3983-3993.
[9]Bernard A, Jin M, Gonz lezRodr guez P, et al. Rph1/KDM4 mediates nutrientlimitation signaling that leads to the transcriptional induction of autophagy\[J\]. Curr Biol, 2015, 25(5): 546-555.
[10]Denton D, AungHtut MT, Lorensuhewa N, et al. UTX coordinates steroid hormonemediated autophagy and cell death\[J\]. Nat Commun, 2013, 4: 2916.
[11]Ambrosio S, Sacc CD, Amente S, et al. Lysinespecific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2dependent pathway\[J\]. Oncogene, 2017, 36(48): 6701-6711.
[12]Byun S, Kim YC, Zhang Y, et al. A postprandial FGF19SHPLSD1 regulatory axis mediates epigenetic repression of hepatic autophagy\[J\]. EMBO J, 2017, 36(12): 1755-1769.
[13]Feng Q, He H, Gao T, et al. Synthesis and biological evaluation of benzomorpholine derivatives as novel EZH2 inhibitors for antinonsmall cell lung cancer activity\[J\]. Mol Divers, 2019, 23(3): 681-696.
[14]Walport LJ, Hopkinson RJ, Schofield CJ. Mechanisms of human histone and nucleic acid demethylases\[J\]. Curr Opin Chem Biol, 2012, 16(5-6): 525-534.
[15]Labb RM, Holowatyj A, Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential\[J\]. Am J Transl Res, 2013, 6(1): 1-15.
[16]Wang B, Fan X, Ma C, et al. Downregulation of KDM4A suppresses the survival of glioma cells by promoting autophagy\[J\]. J Mol Neurosci, 2016, 60(2): 137-144.
[17]Alba MaiquesDiaz, Tim CP Somervaille. LSD1: biologic roles and therapeutic targeting\[J\]. Epigenomics, 2016, 8(8): 1103-1116.
[18]Perillo B, Ombra MN, Bertoni A, et al. DNA oxidation as triggered by H3K9me2 demethylation drives estrogeninduced gene expression\[J\]. Science, 2008, 319(5860): 202-206.
[19]Foster CT, Dovey OM, Lezina L, et al. Lysinespecific demethylase 1 regulates the embryonic transcriptome and CoREST stability\[J\]. Mol Cell Biol, 2010, 30(20): 4851-4863.
[20]Feng S, Jin Y, Cui M , et al. Lysinespecific demethylase 1 (LSD1) inhibitor S2101 induces autophagy via the AKT/mTOR pathway in SKOV3 ovarian cancer cells\[J\]. Med Sci Monit, 2016, 22: 4742-4748.
[21]Etani T, Suzuki T, Naiki T, et al. NCL1, a highly selective lysinespecific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect\[J\]. Oncotarget, 2015, 6(5): 2865-2878.
[22]Wang Z, Long QY, Chen L, et al. Inhibition of H3K4 demethylation induces autophagy in cancer cell lines\[J\]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(12): 2428-2437.
[23]Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function\[J\]. Science, 2009, 325(5939): 473-477.
[24]Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis\[J\]. Science, 2011, 332(6036): 1429-1433.
[25]Wei Y, Han T, Wang R, et al. LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells\[J\]. Oncol Rep, 2018, 40(1): 425-433.
[26]Ambrosio S, Majello B. Targeting histone demethylase LSD1/KDM1a in neurodegenerative diseases\[J\]. J Exp Neurosci, 2018, 12: 1179069518765743.
[27]Periz G, Lu J, Zhang T, et al. Regulation of protein quality control by UBE4B and LSD1 through p53mediated transcription\[J\]. PLoS Biol, 2015, 13(4): e1002114.
[28]Du C, Wu H, Leng RP. UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation\[J\]. Oncotarget, 2016, 7(3): 2823-2836.
[29]Chao A, Lin CY, Chao AN, et al. Lysinespecific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies\[J\]. Oncotarget, 2017, 8(43): 74434-74450.
[30]Li ZR, Wang S, Yang L, et al. Experiencebased discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors\[J\]. Eur J Med Chem, 2019, 166: 432-444.
[31]Wang X, Su M, Li Y, et al. Tranylcypromine and 6trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor\[J\]. Bioorg Med Chem Lett, 2019, 29(6): 844-847.
[32]Li L, Li R, Wang Y. Identification of selective and reversible LSD1 inhibitors with antimetastasis activity by highthroughput docking\[J\]. Bioorg Med Chem Lett, 2019, 29(4): 544-548.
[33]Yang GJ, Lei PM, Wong SY, et al. Pharmacological inhibition of LSD1 for cancer treatment\[J\]. Molecules, 2018, 23(12): 3194.
[34]Wang S, Li ZR, Suo FZ, et al. Synthesis, structureactivity relationship studies and biological characterization of new \[1, 2, 4\]triazolo\[1, 5a\]pyrimidinebased LSD1/KDM1A inhibitors\[J\]. Eur J Med Chem, 2019, 167: 388-401.
[35]Liu S, Lu W, Li S, et al. Identification of JL1037 as a novel, specific, reversible lysinespecific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells\[J\]. Oncotarget, 2017, 8(19): 31901-31914.
[36]Fan JD, Lei PJ, Zheng JY, et al. The selective activation of p53 target genes regulated by SMYD2 in BIX01294 induced autophagyrelated cell death\[J\]. PLoS One, 2015, 10(1): e0116782.
[37]Moosavi A, Motevalizadeh Ardekani A. Role of epigenetics in biology and human diseases\[J\]. Iran Biomed J, 2016, 20(5): 246-258.
|